SCHEMBL16362095

SCHEMBL16362095

Cn1c(=O)oc2cc(-c3ccc(C(=O)Nc4c(F)cncc4F)cc3)c(C3CC3)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.39
▸ CYP11B2 P19099 1/20 0.38
▸ GPR55 Q9Y2T6 2/20 0.35
▸ CRACR2A Q9BSW2 2/20 0.35
▸ HTR1F P30939 3/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR1D P28221 1/20 0.35
▸ HTR1B P28222 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ STIM1 Q13586 1/20 0.35
▸ ORAI1 Q96D31 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ IL2 P60568 2/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ MCHR1 Q99705 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16321066 0.97 KDM1A (0.39) KDM1ACYP11B2GPR55CRACR2AHTR1F
SCHEMBL17766345 0.91 CRACR2A (0.42) KDM1ACRACR2AALDH1A1HPGDSTIM1
SCHEMBL17766361 0.84 CYP11B2 (0.39) KDM1ACYP11B2GPR55ALDH1A1HPGD
SCHEMBL17766354 0.83 CYP11B2 (0.39) KDM1ACYP11B2GPR55ALDH1A1HPGD
SCHEMBL17766365 0.79 IL2 (0.54) CRACR2ASTIM1ORAI1IL2
SCHEMBL17766389 0.78 IL2 (0.49) GPR55CRACR2AHTR1FSTIM1ORAI1
SCHEMBL16362059 0.78 PTGER3 (0.39) CYP11B2GPR55CRACR2AHTR1FHTR1A
SCHEMBL16362422 0.78 PTGER3 (0.39) CYP11B2GPR55
SCHEMBL17766400 0.76 IL2 (0.53) CRACR2ASTIM1ORAI1IL2
SCHEMBL16362086 0.76 IL2 (0.46) ALDH1A1HPGDSTIM1ORAI1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US claimed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US claimed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
WO-2014203217-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2014-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS RYR2, NR2C2, CACNA1E KDM1A 2892/4885CYP11B2 623/4885GPR55 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback